Business
Quantum-Si Begins Commercial Shipments of the PlatinumTM Protein Sequencing System and Provides Business Updates at the 41st Annual J.P. Morgan Healthcare Conference
Company Announces Commercial Shipments of Protein Sequencing System, Reveals New Partnerships, and Reaffirms Commitment to Financial Discipline Launched in
About this update from Quantum-si Incorporated
[{"type":"text","content":"\nCompany Announces Commercial Shipments of Protein Sequencing System, Reveals New Partnerships, and Reaffirms Commitment to Financial Discipline\n\nLaunched in December 2022, Platinum is the First Commercially Available Next-Generation Single-Molecule Protein Sequencing System Looking to Unlock the Proteome One Amino Acid at a Time\n\n GUILFORD, Conn.--(BUSINESS WIRE)--\nQuantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that management will discuss the following business updates at the 41st Annual J.P. Morgan Healthcare Conference.\n\nBusiness Updates\n\n\nQuantum-Si has begun commercial shipments of the Platinum protein sequencing system.\n\n\nThe Company announced a partnership with Aviva Systems Biology, a leading provider of antibody, protein, and immunoassay reagent products, to co-develop sample preparation kits for protein sequencing research workflows with Platinum.\n\n\nQuantum-Si announced a partnership and license agreement with Biovista, an AI-driven bioscience firm, to integrate Biovista’s database and visualization technology into Quantum-Si’s Cloud analytics to advance proteomics research, biomarker discovery, and drug development applications.\n\n\nThe Company reaffirms commitment to fiscal discipline and seeks to extend cash runway beyond the current guidance of 2024.\n\n\n“The launch of our first product is an important inflection point for the Company as we transition from a pure technology development focus to an organization that delivers new products to market while excelling at commercial and operational execution,” said Jeff Hawkins, CEO of Quantum-Si. “Our team is thrilled to have delivered the first orders for Platinum, and we look forward to supporting our growing list of customers in 2023.”\n\nQuantum-Si is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12 at 10:30 am Pacific Standard Time. A live and archived webcast of the events will be available in the Investors section of the Quantum-Si website under Events & Presentations.\n\nAbout Quantum-Si Incorporated\n\nQuantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable n...